



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 12:07
Last Report Issued 07/17/2015 12:28

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1815SP-POS
Patient ID 1815SP-POS
Chain 15001780
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15001780
Received 07/17/2015 12:23

Sample ID 15001780-001
Matrix Serum or Plasma
Patient Name 1815SP-POS
Patient ID 1815SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

1815SP Doxazosin, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Doxazosin	50	ng/mL	2.0	
Synonym(s): Cardura®				

A group of 10 adult hypertensive patients given daily 1, 2, 4 or 8 mg normal-release doses attained steady-state plasma concentrations averaging 19, 42, 79 and 101 ng/mL, respectively, at 1.7-2.7 hours post-dose.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.